Critics of PBMs contend that there is a need for greater levels of “transparency” about the contracts PBMs have with drug companies and retail pharmacies. Many economists disagree. They say that disclosure of the terms of confidential and bargained-for business contracts would inhibit price competition and trample intellectual property rights.